Atorvastatin: NHS prescribing, monitoring and NICE guidance

NICE Clinical Guideline CG181 (Cardiovascular disease: risk assessment and reduction) provides the framework for statin prescribing in England and Wales.

Atorvastatin holds a central position in these recommendations.

Primary prevention (people without existing cardiovascular disease):

• Offer atorvastatin 20 mg to adults with a 10-year QRISK3 cardiovascular risk score of 10% or more
• Use the QRISK3 calculator, which incorporates age, sex, ethnicity, blood pressure, cholesterol, smoking status, diabetes, family history, chronic kidney disease and other factors
• Discuss the benefits and risks with the patient before starting treatment
• Lifestyle modification (diet, exercise, smoking cessation) should always be addressed alongside medication

Secondary prevention (people with existing cardiovascular disease):

• Offer atorvastatin 80 mg to all adults with established cardiovascular disease (previous heart attack, stroke, TIA or peripheral arterial disease)
• Use a lower dose if 80 mg is not tolerated or there is a potential drug interaction
• Treatment should continue indefinitely unless there is a clear reason to stop

Familial hypercholesterolaemia:

• High-intensity statin therapy is recommended for all adults with confirmed familial hypercholesterolaemia
• NICE guideline CG71 provides specific guidance for this condition

In my practice, I always explain the QRISK3 score to patients, showing them how much their absolute risk reduces with treatment.

This shared decision-making approach leads to better adherence and understanding.

Atorvastatin is a prescription-only medicine and is not available over the counter in the UK. Here is how the process typically works in NHS primary care.

The assessment:

1. Your GP or practice nurse will conduct a cardiovascular risk assessment, including blood tests (lipid profile, HbA1c, liver function, renal function, thyroid function)
2. Your QRISK3 score is calculated using the results and your clinical history
3. If your score is 10% or above (or you have existing CVD), statin therapy is discussed

Starting treatment:

• Atorvastatin 20 mg for primary prevention or 80 mg for secondary prevention
• Take at any time of day (unlike simvastatin, which must be taken at night)
• First follow-up blood test at 3 months to check response and liver function

Ongoing prescribing:

• Once established, atorvastatin is issued as a repeat prescription
• Annual review with blood tests is standard
• Most GP practices use electronic repeat dispensing, so you collect your medication monthly from your pharmacy

Cost:

Generic atorvastatin is one of the most cost-effective medications available on the NHS. The drug cost to the NHS is just pence per day.

Patients in England pay the standard prescription charge per item, while prescriptions are free in Scotland, Wales and Northern Ireland.

NHS Health Check:

Adults aged 40 to 74 who do not have a pre-existing condition are entitled to a free NHS Health Check every 5 years.

This includes cardiovascular risk assessment and is often the point at which statin therapy is first discussed.

NICE CG181 provides a clear monitoring schedule for patients on atorvastatin. In my practice, I follow this closely and ensure patients understand what each test is for.

Before starting treatment:

• Full lipid profile (total cholesterol, HDL, non-HDL, triglycerides)
• Liver function tests (ALT, AST)
• HbA1c or fasting glucose
• Renal function (eGFR, creatinine)
• Thyroid function (to exclude hypothyroidism as a cause of raised cholesterol)

At 3 months:

• Repeat lipid profile: NICE recommends aiming for a greater than 40% reduction in non-HDL cholesterol from baseline
• Liver function tests: if ALT/AST exceed 3 times the upper limit of normal, stop atorvastatin and investigate
• Review adherence and any side effects

At 12 months:

• Repeat lipid profile and liver function tests
• HbA1c to monitor for new-onset diabetes
• Renal function

Annually thereafter:

• Lipid profile
• HbA1c
• Renal function
• Liver function tests are no longer routinely required unless clinically indicated
• Review cardiovascular risk factors and medication adherence

Additional tests if symptomatic:

• CK (creatine kinase): only if the patient reports muscle symptoms. Routine CK monitoring is not recommended
• Vitamin D: consider checking in patients with muscle symptoms, as deficiency can mimic statin myopathy

NICE emphasises that atorvastatin should always be prescribed as part of a comprehensive cardiovascular risk reduction strategy. Medication alone is not sufficient.

Diet:

• Follow a Mediterranean-style diet rich in fruits, vegetables, whole grains, oily fish, nuts and olive oil
• Reduce saturated fat intake (butter, cheese, fatty meats, processed foods)
• Include plant stanols and sterols (found in fortified spreads) which can reduce LDL cholesterol by up to 10%
• Limit alcohol to within recommended guidelines (14 units per week)

Physical activity:

• Aim for at least 150 minutes of moderate-intensity aerobic activity per week (brisk walking, cycling, swimming)
• Include muscle-strengthening activities on 2 or more days per week
• Even modest increases in activity provide cardiovascular benefit

Smoking cessation:

• Smoking is the single most modifiable cardiovascular risk factor
• The NHS Stop Smoking Service is available free of charge and significantly improves quit rates
• Stopping smoking reduces cardiovascular risk within weeks

Blood pressure management:

• If you have hypertension, ensure it is well controlled
• Amlodipine is a common companion medication (see our amlodipine guide)

Weight management:

• Maintaining a healthy BMI reduces cardiovascular risk independently of cholesterol levels
• NHS weight management services are available through your GP

I always tell patients that atorvastatin works best as part of a team effort. The pill does its part, but lifestyle changes multiply its benefit.

Not every patient tolerates atorvastatin, and the NHS provides clear pathways for those who need an alternative.

Switching to another statin:

If atorvastatin causes intolerable side effects, your GP may suggest:

• Rosuvastatin: a potent alternative with a different metabolic pathway (not metabolised by CYP3A4)
• Pravastatin: less potent but better tolerated by some patients, particularly for muscle symptoms
• Simvastatin: an older option, now less commonly used as first-line due to more drug interactions

NICE recommends trying at least one alternative statin before concluding that a patient is statin-intolerant.

Non-statin options:

• Ezetimibe: reduces cholesterol absorption from the gut, often used alongside a reduced statin dose or as monotherapy in truly statin-intolerant patients
• PCSK9 inhibitors (alirocumab, evolocumab): highly effective injectable treatments available through specialist lipid clinics for patients who cannot achieve target cholesterol levels. NICE TA393 and TA394 provide the criteria for NHS funding
• Bempedoic acid: a newer oral option (NICE TA694) for patients who cannot tolerate statins, often combined with ezetimibe
• Inclisiran: a twice-yearly injection (NICE TA733) available for secondary prevention in patients not achieving targets

The key message is that there is always an alternative if atorvastatin is not right for you. Speak to your GP rather than simply stopping treatment.